Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib-resistant HCC are not systemically identified. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhi-Yong, Zhang, Dan-Ying, Lin, Xia-Hui, Sun, Jia-Lei, Abuduwaili, Weinire, Zhang, Guang-Cong, Xu, Ru-Chen, Wang, Fu, Yu, Xiang-Nan, Shi, Xuan, Deng, Bin, Dong, Ling, Weng, Shu-Qiang, Zhu, Ji-Min, Shen, Xi-Zhong, Liu, Tao-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441713/
https://www.ncbi.nlm.nih.gov/pubmed/36071851
http://dx.doi.org/10.3389/fphar.2022.952482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441713/
https://www.ncbi.nlm.nih.gov/pubmed/36071851
http://dx.doi.org/10.3389/fphar.2022.952482

Ejemplares similares